Cardio Day for a Card Giant, Here’s The Play Now

Revenue ran a lap and guidance kept pace.

Fun chart, but gravity exists. Add on pullbacks toward the last base and let KPIs tell you when to press.

Clarity At Last (Sponsored)

Washington Finally Delivers Crypto Clarity

The uncertainty that held back institutional adoption is gone.

With structured federal policy in place, Wall Street has no excuse left to stay out.

That’s why major banks are preparing to launch crypto products.

Get the strategies insiders are using—free inside our Crypto Revolution book.

[Claim your copy here]

© 2025 Boardwalk Flock LLC. All Rights Reserved. 2382 Camino Vida Roble, Suite I Carlsbad, CA 92011, United States

The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Readers acknowledge that the authors are not engaging in the rendering of legal, financial, medical, or professional advice. The reader agrees that under no circumstances Boardwalk Flock, LLC is responsible for any losses, direct or indirect, which are incurred as a result of the use of the information contained within this, including, but not limited to, errors, omissions, or inaccuracies.

Results may not be typical and may vary from person to person. Making money trading digital currencies takes time and hard work. There are inherent risks involved with investing, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk.

Never Miss a Stock Alert Again!

We now send our daily picks via SMS too — so you’ll get the same high-conviction ideas, even if you miss the email.

👉 Click here to get stock picks by text and stay in the loop, always.

Gilead Sciences | GILD

Price: $123.13

HIV remains the cash engine, now with longer exclusivity, while oncology is the torque that can shift the story from steady to spicy.

After the breakout, the play is simple: buy pullbacks toward $120 and let earnings and trial updates do the work.

Track Biktarvy revenue, new patient adds, and pricing dynamics, then stack oncology KPIs like Trodelvy growth, line extensions, and trial catalysts. 

Gross margin strength and disciplined opex matter because they fund the pipeline without stressing the balance sheet.

Use position sizing that respects biotech headline risk and plan trims into fast spikes. Covered calls can pay you to wait if news flow pauses.

Why it matters to you: You’re buying a defensible cash generator with pipeline upside.

If oncology execution steps up, the base case gets better without multiple heroics.

Oracle | ORCL

Price: $277.15

The stock slipped as management laid out big AI and cloud ambitions with heavy capex up front.

That is fine if you treat it like a builder’s story. Accumulate on weakness into support and make capex cadence, OCI revenue growth, and margin mix earn each add. 

On your dashboard is the remaining performance obligations, cloud infrastructure growth vs. peers, and free cash flow trajectory as new capacity switches from cash out to cash in. 

Cerner integration and cloud applications cross-sell are quiet tailwinds that can help buffer the build cycle.

If backlog converts and FCF inflects, multiple risk fades and estimates rise without rerating doing all the lifting.

Until then, keep a leash through prints and trim into sharp squeezes.

Why it matters to you: If Oracle converts AI infrastructure commitments into durable, high-margin cloud dollars, you own an underappreciated compounding engine.

High Growth Phases (Sponsored)

5 Market Leaders Entering High-Growth Phases

Your portfolio might be doing fine. But why stop at fine when you could aim for game-changing gains?

Our analysts have just released a new special report, highlighting 5 stocks with the potential to double.

These aren’t random picks.

They were hand-selected because they combine:

• Proven fundamentals with long-term staying power

• Technical strength suggesting momentum is building now

Past reports have pinpointed stocks before huge runs of +175%, +498%, even +673%.¹

This exclusive report is yours free—but only until midnight tonight.

[Click here now to download your copy instantly]

Why settle for average when extraordinary is on the table?

Newmont | NEM

Price: $94.90

Gold soared and NEM followed. Great, but vertical candles rarely make the best entries.

Set a buy-the-dip plan in the mid-80s to low-90s and let Q3 confirm the operating torque.

Track AISC, grade, and volumes across key sites, balance-sheet flexibility, and any copper by-product color that adds earnings diversification. 

If bullion stays elevated and costs stay contained, earnings power steps up again and dividend flexibility improves.

You can finance patience with covered calls, and a small put spread hedge into prints keeps sleep quality high.

If gold cools, keep dry powder for a better reset.

Why it matters to you: Miners have real operating leverage to the metal.

Entries and risk controls matter more than opinions when charts go parabolic.

Capital One Financial | COF

Price: $214.84

Analysts warmed to credit trends and buybacks, but GAAP optics are messy and the headline P/E looks odd because of recent losses.

Treat it like a credit-cycle trade with catalysts.

Add on weakness only if net charge-offs and delinquencies behave, reserve builds stabilize, and Discover integration milestones hit on time. 

Monthly credit updates, funding costs, and card loan growth are your tell.

The setup improves fast if rates drift lower and consumer stress eases, but be ready to trim if unemployment or loss curves tick up. 

Consider a modest put spread into earnings if you sized up, and keep a stop under recent support so one bad print does not ruin your quarter.

Why it matters to you: If credit normalizes and synergies land, earnings power can rebuild faster than the headline multiple suggests.

American Express | AXP

Price: $349.33

AXP beat on EPS and revenue and raised full-year guidance.

Premium cardholders are still swiping for travel, dining, and experiences, and annual card fees keep climbing, which lifts durability in a slower macro.

The plan stays the same, do not chase fresh highs. 

Build on red days into the prior breakout zone and size to volatility.

Your scoreboard is card-fee growth, billed business momentum (especially T&E), and stable write-offs and delinquencies.

Also watch international merchant acceptance and new product uptake; both help sustain double-digit revenue compounding. 

If guidance holds and loss rates stay contained, let winners run and trail a stop so you keep gains if sentiment cools.

Valuation is not cheap, so make the business earn each add with data.

Why it matters to you: A quality compounder tied to premium spend.

If the guide sticks, the multiple can hold and the stock can grind higher.

Today’s mix blends quality with catalysts. AXP is your premium-spend barometer that rewards patience on pullbacks.

GILD offers defensible cash flow with pipeline torque. ORCL is a capex-now, cash-later project that can re-rate if backlog turns to FCF. 

NEM is pure leverage to gold, so let price come to you. COF is a credit call, make metrics, not vibes, decide your size.

Stagger entries, keep stops honest, and let operating data tell you when to press or lighten up.

Stat of the Day: 40%

From the April lows to October 17, the S&P 500 rallied about 40% and notched 33 new all-time highs this year.

In a tape like this, honor trends, but don’t forget drawdown math.

Scale in, buy weakness in names with cash flow and catalysts, and keep some cash for the inevitable shakeouts.